Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
about
Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?Understanding heart failure with preserved ejection fraction: where are we today?Myocardial hypertrophy and its role in heart failure with preserved ejection fractionModulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase ActivityCardiovascular proteomics in the era of big data: experimental and computational advancesPathophysiology of Aortic Valve Stenosis: Is It Both Fibrocalcific and Sex Specific?Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line.Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate.Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling networkPhenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.CYP2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPKα2 and enhancing nuclear translocation of Akt1.Effect of asymmetric dimethylarginine (ADMA) on heart failure development.PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction.Unbalanced Oxidant-Antioxidant Status: A Potential Therapeutic Target for Coronary Chronic Total Occlusion in Very Old Patients.From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials.cUMP hydrolysis by PDE3A.Potential Expanded Indications for Neprilysin Inhibitors.Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.Myocardial reverse remodeling: how far can we rewind?Molecular Physiology of Membrane Guanylyl Cyclase Receptors.Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Proteomics Research in Cardiovascular Medicine and Biomarker Discovery.International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.Cardiomyocyte Ca2+ homeostasis as a therapeutic target in heart failure with reduced and preserved ejection fraction.Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1.Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine.Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation.Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.Impaired cAMP-cGMP cross-talk during cardiac sympathetic dysautonomia.Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.Role of PDE9 in Cognition.Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes.Can Nitrite AMPk Up Sirt-ainty to Treat Heart Failure With Preserved Ejection Fraction?
P2860
Q26765931-8F2E3390-446F-4E3B-B3E8-4627F0EDDE66Q26766590-D7057774-4A2C-40F2-8961-650CA836B568Q26800076-B74C6D6A-AB0E-4F18-8B0F-96ED64E2A019Q28073080-8562E5E6-4913-49D7-8190-4D011E17B66BQ28074789-E6541475-172B-4960-A3CF-61E989FD1012Q30234828-65F4E3D5-C5DE-4CF6-A884-F1CB68C21336Q36293532-FF52B5F9-6D3D-4F2B-8370-A1FDDFFA79DBQ36296869-A9B90C20-BF1F-40DC-B67C-7494E65512E1Q36609843-7710350A-DB5D-4B35-93A7-47322A8D3E82Q37058596-96F9414A-4F67-4764-818C-6B53CA4785BEQ37075920-1EF99EB7-7573-4069-B69D-A9EBCD9F1BF9Q37235552-19CD881E-7EA3-48EA-B614-80A3882D127BQ37245523-D2F2EC0C-8EE7-44F8-9C38-148F9D4CF930Q37417757-F75073CB-7C3C-43EF-9F7C-F4EFAFB30A62Q37504067-CA4A7B85-8713-4F88-914A-230DCC30EB7FQ38612665-6C0EB3BD-738A-4660-AC16-4D837FE89BAFQ38670275-F97E7110-FD56-4757-A6E7-3D7B4403F4F5Q38726170-13DE7397-5B84-401A-9C72-CD3EE8C6912BQ38747742-E756D0A2-523D-492F-B788-FEC16F82424BQ38750251-020C3241-6D61-4099-BA2C-E4D205D21A90Q38780883-9BDDF7A4-E7CB-4E5F-86F0-DF9BA674F9C7Q38794203-9A94FFBF-7C6D-46A5-B912-268B09C57447Q38862807-8E11C975-E99E-4E7B-95C9-C17C8659B68AQ38992600-8117AC55-F3B3-45FB-81B2-3B171D0E113FQ39050547-81BF85AD-64D2-407E-A3A5-C7D4C04D5DD0Q39158851-3C72000C-6FF0-4617-BE2C-58F21B7D68D9Q39258979-36187224-C349-4961-987F-C9F2810D71BFQ39268911-4CBDACC3-A1DA-49F1-8471-DDD919871638Q39721664-ED94CF6C-BE10-464C-BC59-AC8BA51D96FFQ40580301-3CFF38C9-45A7-4C4E-862A-B5B76F60B328Q41045943-AD62983D-D1CE-40E6-8884-7E7E9F549B90Q41126307-209501DB-BA9B-4582-830E-2B34C3FD65B1Q42513803-F480A16A-AB70-4367-9497-B48A234B7803Q43181566-6F5EB9ED-6E95-4809-BB6D-6B6D333BBA2BQ45305673-1938D11B-F296-4DC9-B072-059249A8882CQ46299650-D9E2619F-6FD0-49CD-BFD3-5251C2C81C08Q47890686-5F713162-1604-4168-B18E-F8CE018EF1C4Q47987941-0EEC6F6C-5270-415D-A746-3424EDDA7F40Q49787366-1DFFDFBD-8E59-48E7-A2C5-1754BD394A12Q51545876-D9E3D1FB-FE8E-4936-82AB-6D6443DA2D34
P2860
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@ast
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@en
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@en-gb
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@nl
type
label
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@ast
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@en
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@en-gb
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@nl
prefLabel
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@ast
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@en
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@en-gb
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Phosphodiesterase 9A controls ...... and hypertrophic heart disease
@en
P2093
Chulan Kwon
David A Kass
Djahida Bedja
Dong I Lee
Eiki Takimoto
Guangshuo Zhu
Gun-Sik Cho
Jennifer E Van Eyk
Kenneth B Margulies
Manling Zhang
P2860
P2888
P304
P3181
P356
10.1038/NATURE14332
P407
P577
2015-03-26T00:00:00Z
P6179
1000839979